Safety, tolerability, and efficacy of an in-class combination therapy switch from bosentan plus sildenafil to ambrisentan plus tadalafil in children with pulmonary arterial hypertension.

For children on triple therapy with a prostanoid, 27% were in WHO FC III/IV at baseline assessment compared to no children at post‐switch completion assessment at 12.2 [12.0, 13.5] weeks, although this did not reach statistical significance.

also in 111,027 other papers